[Chronic heart failure and sudden death: the message of CIBIS-III]

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Heart failure presents a significant socio-economic burden globally.
• Neurohormonal modulation is a key pharmacological strategy for heart failure management.
• Implantable devices are increasingly used, posing challenges for integrated treatment schemes.

Purpose of the Study:

• To evaluate beta-blocker therapy as a primary approach in heart failure.
• To assess the efficacy of bisoprolol prior to ACE inhibitors, particularly in patients with sympathetic hyperactivity.
• To explore bisoprolol's effectiveness in chronic heart failure without concomitant enalapril.

Main Methods:

• The CIBIS-III trial investigated the use of bisoprolol as a first-line treatment.
• Comparison of bisoprolol initiated before or concurrently with ACE inhibitors.
• Focus on patients with chronic heart failure and evidence of autonomic imbalance.

Main Results:

• Bisoprolol can be used as a primary approach in chronic heart failure patients.
• Initiating bisoprolol first allows for faster achievement of optimal anti-adrenergic doses.
• This strategy is effective in reducing sudden death and implantable cardioverter-defibrillator discharges.
• Bisoprolol showed efficacy even without concurrent enalapril therapy.

Conclusions:

• Beta-blocker therapy, exemplified by bisoprolol, can be a primary strategy in heart failure management.
• Early use of bisoprolol optimizes anti-arrhythmic effects and addresses sympathetic hyperactivity.
• Findings suggest a revision of current international heart failure guidelines.